These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 19781947

  • 1. Glucose-based spiro-isoxazolines: a new family of potent glycogen phosphorylase inhibitors.
    Benltifa M, Hayes JM, Vidal S, Gueyrard D, Goekjian PG, Praly JP, Kizilis G, Tiraidis C, Alexacou KM, Chrysina ED, Zographos SE, Leonidas DD, Archontis G, Oikonomakos NG.
    Bioorg Med Chem; 2009 Oct 15; 17(20):7368-80. PubMed ID: 19781947
    [Abstract] [Full Text] [Related]

  • 2. 1-(3-Deoxy-3-fluoro-beta-d-glucopyranosyl) pyrimidine derivatives as inhibitors of glycogen phosphorylase b: Kinetic, crystallographic and modelling studies.
    Tsirkone VG, Tsoukala E, Lamprakis C, Manta S, Hayes JM, Skamnaki VT, Drakou C, Zographos SE, Komiotis D, Leonidas DD.
    Bioorg Med Chem; 2010 May 15; 18(10):3413-25. PubMed ID: 20430629
    [Abstract] [Full Text] [Related]

  • 3. Crystallographic and computational studies on 4-phenyl-N-(beta-D-glucopyranosyl)-1H-1,2,3-triazole-1-acetamide, an inhibitor of glycogen phosphorylase: comparison with alpha-D-glucose, N-acetyl-beta-D-glucopyranosylamine and N-benzoyl-N'-beta-D-glucopyranosyl urea binding.
    Alexacou KM, Hayes JM, Tiraidis C, Zographos SE, Leonidas DD, Chrysina ED, Archontis G, Oikonomakos NG, Paul JV, Varghese B, Loganathan D.
    Proteins; 2008 May 15; 71(3):1307-23. PubMed ID: 18041758
    [Abstract] [Full Text] [Related]

  • 4. Glycogen phosphorylase inhibitors: a free energy perturbation analysis of glucopyranose spirohydantoin analogues.
    Archontis G, Watson KA, Xie Q, Andreou G, Chrysina ED, Zographos SE, Oikonomakos NG, Karplus M.
    Proteins; 2005 Dec 01; 61(4):984-98. PubMed ID: 16245298
    [Abstract] [Full Text] [Related]

  • 5. Kinetic and crystallographic studies of glucopyranose spirohydantoin and glucopyranosylamine analogs inhibitors of glycogen phosphorylase.
    Watson KA, Chrysina ED, Tsitsanou KE, Zographos SE, Archontis G, Fleet GW, Oikonomakos NG.
    Proteins; 2005 Dec 01; 61(4):966-83. PubMed ID: 16222658
    [Abstract] [Full Text] [Related]

  • 6. Sourcing the affinity of flavonoids for the glycogen phosphorylase inhibitor site via crystallography, kinetics and QM/MM-PBSA binding studies: comparison of chrysin and flavopiridol.
    Tsitsanou KE, Hayes JM, Keramioti M, Mamais M, Oikonomakos NG, Kato A, Leonidas DD, Zographos SE.
    Food Chem Toxicol; 2013 Nov 01; 61():14-27. PubMed ID: 23279842
    [Abstract] [Full Text] [Related]

  • 7. Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.
    Goyard D, Kónya B, Chajistamatiou AS, Chrysina ED, Leroy J, Balzarin S, Tournier M, Tousch D, Petit P, Duret C, Maurel P, Somsák L, Docsa T, Gergely P, Praly JP, Azay-Milhau J, Vidal S.
    Eur J Med Chem; 2016 Jan 27; 108():444-454. PubMed ID: 26708111
    [Abstract] [Full Text] [Related]

  • 8. Glucose analogue inhibitors of glycogen phosphorylase: from crystallographic analysis to drug prediction using GRID force-field and GOLPE variable selection.
    Watson KA, Mitchell EP, Johnson LN, Cruciani G, Son JC, Bichard CJ, Fleet GW, Oikonomakos NG, Kontou M, Zographos SE.
    Acta Crystallogr D Biol Crystallogr; 1995 Jul 01; 51(Pt 4):458-72. PubMed ID: 15299833
    [Abstract] [Full Text] [Related]

  • 9. Ternary complex crystal structures of glycogen phosphorylase with the transition state analogue nojirimycin tetrazole and phosphate in the T and R states.
    Mitchell EP, Withers SG, Ermert P, Vasella AT, Garman EF, Oikonomakos NG, Johnson LN.
    Biochemistry; 1996 Jun 11; 35(23):7341-55. PubMed ID: 8652510
    [Abstract] [Full Text] [Related]

  • 10. Crystallographic studies on two bioisosteric analogues, N-acetyl-beta-D-glucopyranosylamine and N-trifluoroacetyl-beta-D-glucopyranosylamine, potent inhibitors of muscle glycogen phosphorylase.
    Anagnostou E, Kosmopoulou MN, Chrysina ED, Leonidas DD, Hadjiloi T, Tiraidis C, Zographos SE, Györgydeák Z, Somsák L, Docsa T, Gergely P, Kolisis FN, Oikonomakos NG.
    Bioorg Med Chem; 2006 Jan 01; 14(1):181-9. PubMed ID: 16213146
    [Abstract] [Full Text] [Related]

  • 11. 3'-axial CH2 OH substitution on glucopyranose does not increase glycogen phosphorylase inhibitory potency. QM/MM-PBSA calculations suggest why.
    Manta S, Xipnitou A, Kiritsis C, Kantsadi AL, Hayes JM, Skamnaki VT, Lamprakis C, Kontou M, Zoumpoulakis P, Zographos SE, Leonidas DD, Komiotis D.
    Chem Biol Drug Des; 2012 May 01; 79(5):663-73. PubMed ID: 22296957
    [Abstract] [Full Text] [Related]

  • 12. Advances in glycogen phosphorylase inhibitor design.
    Oikonomakos NG, Somsák L.
    Curr Opin Investig Drugs; 2008 Apr 01; 9(4):379-95. PubMed ID: 18393105
    [Abstract] [Full Text] [Related]

  • 13. The binding of β-d-glucopyranosyl-thiosemicarbazone derivatives to glycogen phosphorylase: A new class of inhibitors.
    Alexacou KM, Tenchiu Deleanu AC, Chrysina ED, Charavgi MD, Kostas ID, Zographos SE, Oikonomakos NG, Leonidas DD.
    Bioorg Med Chem; 2010 Nov 15; 18(22):7911-22. PubMed ID: 20947361
    [Abstract] [Full Text] [Related]

  • 14. Modeling aided design of potent glycogen phosphorylase inhibitors.
    Deng Q, Lu Z, Bohn J, Ellsworth KP, Myers RW, Geissler WM, Harris G, Willoughby CA, Chapman K, McKeever B, Mosley R.
    J Mol Graph Model; 2005 Apr 15; 23(5):457-64. PubMed ID: 15781188
    [Abstract] [Full Text] [Related]

  • 15. Thermodynamic characterization of allosteric glycogen phosphorylase inhibitors.
    Anderka O, Loenze P, Klabunde T, Dreyer MK, Defossa E, Wendt KU, Schmoll D.
    Biochemistry; 2008 Apr 22; 47(16):4683-91. PubMed ID: 18373353
    [Abstract] [Full Text] [Related]

  • 16. Discovering benzamide derivatives as glycogen phosphorylase inhibitors and their binding site at the enzyme.
    Chen L, Li H, Liu J, Zhang L, Liu H, Jiang H.
    Bioorg Med Chem; 2007 Nov 01; 15(21):6763-74. PubMed ID: 17719791
    [Abstract] [Full Text] [Related]

  • 17. Novel design principle validated: glucopyranosylidene-spiro-oxathiazole as new nanomolar inhibitor of glycogen phosphorylase, potential antidiabetic agent.
    Somsák L, Nagy V, Vidal S, Czifrák K, Berzsényi E, Praly JP.
    Bioorg Med Chem Lett; 2008 Oct 15; 18(20):5680-3. PubMed ID: 18793852
    [Abstract] [Full Text] [Related]

  • 18. Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site.
    Kristiansen M, Andersen B, Iversen LF, Westergaard N.
    J Med Chem; 2004 Jul 01; 47(14):3537-45. PubMed ID: 15214781
    [Abstract] [Full Text] [Related]

  • 19. A multidisciplinary study of 3-(β-d-glucopyranosyl)-5-substituted-1,2,4-triazole derivatives as glycogen phosphorylase inhibitors: Computation, synthesis, crystallography and kinetics reveal new potent inhibitors.
    Kun S, Begum J, Kyriakis E, Stamati ECV, Barkas TA, Szennyes E, Bokor É, Szabó KE, Stravodimos GA, Sipos Á, Docsa T, Gergely P, Moffatt C, Patraskaki MS, Kokolaki MC, Gkerdi A, Skamnaki VT, Leonidas DD, Somsák L, Hayes JM.
    Eur J Med Chem; 2018 Mar 10; 147():266-278. PubMed ID: 29453094
    [Abstract] [Full Text] [Related]

  • 20. Prediction of ligand-receptor binding thermodynamics by free energy force field three-dimensional quantitative structure-activity relationship analysis: applications to a set of glucose analogue inhibitors of glycogen phosphorylase.
    Venkatarangan P, Hopfinger AJ.
    J Med Chem; 1999 Jun 17; 42(12):2169-79. PubMed ID: 10377222
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.